SHANDONG XINHUA (00719) Announces Approval for Entacapone Tablets

Bulletin Express03-04 17:16

SHANDONG XINHUA (00719) has received a Drug Registration Certificate for its Entacapone Tablets from the National Medical Products Administration. According to the announcement dated 4 March 2026, the approved specification is 0.20g in tablet form, registered under Class 4 chemicals.

Entacapone Tablets serve as an adjunct to standard levodopa-based regimens, targeting Parkinson’s disease and end-dose phenomenon that cannot be managed by standard therapies alone. The product is included as a Category B treatment in the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2025).

Official data indicate that sales of Entacapone Tablets in China’s public medical institutions totaled approximately 286.00 million yuan in 2024. The management notes that this newly approved certificate will help enrich the company’s antiviral drug product lineup and strengthen its overall market competitiveness. However, the company points out that pharmaceutical sales may be influenced by changes in industry policies, bidding processes, and market conditions, signaling uncertainties in future performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100492962?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 17:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100492962","market":"us","top_or_hot":-1,"title":"SHANDONG XINHUA (00719) Announces Approval for Entacapone Tablets","media":"Bulletin Express","content":"<p>SHANDONG XINHUA (00719) has received a Drug Registration Certificate for its Entacapone Tablets from the National Medical Products Administration. According to the announcement dated 4 March 2026, the approved specification is 0.20g in tablet form, registered under Class 4 chemicals.</p>\n<p>Entacapone Tablets serve as an adjunct to standard levodopa-based regimens, targeting Parkinson’s disease and end-dose phenomenon that cannot be managed by standard therapies alone. The product is included as a Category B treatment in the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2025).</p>\n<p>Official data indicate that sales of Entacapone Tablets in China’s public medical institutions totaled approximately 286.00 million yuan in 2024. The management notes that this newly approved certificate will help enrich the company’s antiviral drug product lineup and strengthen its overall market competitiveness. However, the company points out that pharmaceutical sales may be influenced by changes in industry policies, bidding processes, and market conditions, signaling uncertainties in future performance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SHANDONG XINHUA (00719) Announces Approval for Entacapone Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSHANDONG XINHUA (00719) Announces Approval for Entacapone Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-04 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANDONG XINHUA (00719) has received a Drug Registration Certificate for its Entacapone Tablets from the National Medical Products Administration. According to the announcement dated 4 March 2026, the approved specification is 0.20g in tablet form, registered under Class 4 chemicals.</p>\n<p>Entacapone Tablets serve as an adjunct to standard levodopa-based regimens, targeting Parkinson’s disease and end-dose phenomenon that cannot be managed by standard therapies alone. The product is included as a Category B treatment in the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2025).</p>\n<p>Official data indicate that sales of Entacapone Tablets in China’s public medical institutions totaled approximately 286.00 million yuan in 2024. The management notes that this newly approved certificate will help enrich the company’s antiviral drug product lineup and strengthen its overall market competitiveness. However, the company points out that pharmaceutical sales may be influenced by changes in industry policies, bidding processes, and market conditions, signaling uncertainties in future performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00719","symbol_name":"山东新华制药股份","start_time":0,"source_url":"","article_id":"1100492962","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100492962","pubTimestamp":1772615781,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"SHANDONG XINHUA (00719) has received a Drug Registration Certificate for its Entacapone Tablets from the National Medical Products Administration. According to the announcement dated 4 March 2026,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00719":"山东新华制药股份"},"translate_title":"山东新华(00719)公布恩他卡朋片获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"SHANDONG XINHUA (00719) has received a Drug Registration Certificate for its Entacapone Tablets from the National Medical Products Administration. According to the announcement dated 4 March 2026, the approved specification is 0.20g in tablet form, registered under Class 4 chemicals.\nEntacapone Tablets serve as an adjunct to standard levodopa-based regimens, targeting Parkinson’s disease and end-dose phenomenon that cannot be managed by standard therapies alone. The product is included as a Category B treatment in the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2025).\nOfficial data indicate that sales of Entacapone Tablets in China’s public medical institutions totaled approximately 286.00 million yuan in 2024. The management notes that this newly approved certificate will help enrich the company’s antiviral drug product lineup and strengthen its overall market competitiveness. However, the company points out that pharmaceutical sales may be influenced by changes in industry policies, bidding processes, and market conditions, signaling uncertainties in future performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100492962","isCrawlerRequest":true}